Global pharmaceutical company Eli Lilly (NYSE:LLY) reported revenue ahead of Wall Streets expectations in Q3 CY2025, with ...

Eli Lilly (NYSE: LLY) delivered a commanding third quarter, posting earnings and revenue that significantly exceeded ...

The results come as Eli Lilly works to maintain its edge over Novo Nordisk in the booming market for a class of obesity and ...

Eli Lilly (NYSE:LLY) shares rose 6% in the premarket on Thursday after the drugmaker beat Wall Street expectations with its ...

Johnson & Johnson (NYSE:JNJ) and Eli Lilly (NYSE:LLY) are utilizing Nvidia technology to either enhance their products or ...

A particularly noteworthy achievement emerged this quarter: Eli Lilly's tirzepatide franchise overtook Merck's cancer immunotherapy Keytruda to become the world's highest-grossing medication. This ...

Discover Eli Lilly’s Q3 2025 earnings highlights: record 54% revenue growth, new product approvals, raised guidance, and global expansion.

CEO David Ricks wants Eli Lilly’s upcoming obesity pill to be accessible to patients who need it, but the company still needs ...

Eli Lilly beats Q3 2025 estimates and raises guidance as strong GLP-1 drug sales from Mounjaro and Zepbound lift profit and ...

Together, Mounjaro and Zepbound brought in $11.98 billion in the third quarter even with price decreases for the medicines.

The Eli Lilly and Company will acquire Adverum Biotechnologies, according to a joint press release issued by the 2 companies.

Now, let’s talk about the real contenders, okay. Let’s start with Eli Lilly, one I always said was going to get to trillion ...